JP2018535394A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535394A5
JP2018535394A5 JP2018514414A JP2018514414A JP2018535394A5 JP 2018535394 A5 JP2018535394 A5 JP 2018535394A5 JP 2018514414 A JP2018514414 A JP 2018514414A JP 2018514414 A JP2018514414 A JP 2018514414A JP 2018535394 A5 JP2018535394 A5 JP 2018535394A5
Authority
JP
Japan
Prior art keywords
lcn2
patient
disease
level
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018514414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535394A (ja
JP6909208B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/052060 external-priority patent/WO2017049035A1/en
Publication of JP2018535394A publication Critical patent/JP2018535394A/ja
Publication of JP2018535394A5 publication Critical patent/JP2018535394A5/ja
Priority to JP2021110695A priority Critical patent/JP7153775B2/ja
Application granted granted Critical
Publication of JP6909208B2 publication Critical patent/JP6909208B2/ja
Priority to JP2022159196A priority patent/JP2023002583A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018514414A 2015-09-17 2016-09-16 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 Expired - Fee Related JP6909208B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021110695A JP7153775B2 (ja) 2015-09-17 2021-07-02 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP2022159196A JP2023002583A (ja) 2015-09-17 2022-10-03 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562220062P 2015-09-17 2015-09-17
US62/220,062 2015-09-17
PCT/US2016/052060 WO2017049035A1 (en) 2015-09-17 2016-09-16 Prediction of clinical response to il23-antagonists using il23 pathway biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021110695A Division JP7153775B2 (ja) 2015-09-17 2021-07-02 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測

Publications (3)

Publication Number Publication Date
JP2018535394A JP2018535394A (ja) 2018-11-29
JP2018535394A5 true JP2018535394A5 (https=) 2020-11-12
JP6909208B2 JP6909208B2 (ja) 2021-07-28

Family

ID=58289919

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018514414A Expired - Fee Related JP6909208B2 (ja) 2015-09-17 2016-09-16 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP2021110695A Active JP7153775B2 (ja) 2015-09-17 2021-07-02 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP2022159196A Pending JP2023002583A (ja) 2015-09-17 2022-10-03 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021110695A Active JP7153775B2 (ja) 2015-09-17 2021-07-02 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP2022159196A Pending JP2023002583A (ja) 2015-09-17 2022-10-03 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測

Country Status (13)

Country Link
US (1) US11016099B2 (https=)
EP (1) EP3349854A4 (https=)
JP (3) JP6909208B2 (https=)
KR (1) KR20180063127A (https=)
CN (2) CN116672446A (https=)
AU (1) AU2016323579A1 (https=)
BR (1) BR112018005175A2 (https=)
CA (1) CA2998349A1 (https=)
HK (1) HK1258292A1 (https=)
IL (1) IL257969A (https=)
MX (1) MX2018003376A (https=)
RU (1) RU2018113694A (https=)
WO (1) WO2017049035A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2016054038A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019113037A1 (en) * 2017-12-04 2019-06-13 Immusant, Inc. Measurement of ccl20 after gluten exposure
CA3085000A1 (en) * 2017-12-07 2019-06-13 Amgen Inc. Method of treating idiopathic thrombocytopenia purpura (itp) with romiplostim
CA3092551A1 (en) * 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
EP3793521A4 (en) 2018-05-18 2022-02-23 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
WO2020016838A2 (en) * 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
BR112021005467A2 (pt) * 2018-09-24 2021-06-22 Janssen Biotech, Inc. método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
WO2020104705A2 (en) * 2018-11-23 2020-05-28 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
CN109337974B (zh) * 2018-12-14 2022-01-25 北京蛋白质组研究中心 一种检测银屑病的诊断标志物的试剂及其应用
US20200197517A1 (en) * 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
MX2021011328A (es) * 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
CN113710316A (zh) * 2019-03-26 2021-11-26 阿斯特捷利康合作创业有限责任公司 适合于il23拮抗剂疗法的患者群体
EP3956358A4 (en) * 2019-04-17 2023-01-25 Millennium Pharmaceuticals, Inc. COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
US20210079086A1 (en) * 2019-08-21 2021-03-18 Astrazeneca Collaboration Ventures, Llc Use of Brazikumab to Treat Crohn's Disease
CN114555120A (zh) * 2019-10-18 2022-05-27 詹森生物科技公司 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法
WO2021106453A1 (ja) * 2019-11-29 2021-06-03 東洋紡株式会社 組換えｃ反応性タンパク質
CA3164996A1 (en) * 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
CA3170677A1 (en) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
CN111424086A (zh) * 2020-03-19 2020-07-17 上海交通大学 用于胃癌诊断及预后评估的生物标记物及应用和检测试剂盒
WO2021207725A1 (en) * 2020-04-10 2021-10-14 The Johns Hopkins University Lipocalin-2 assay for intestinal adaptation
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
US20230391863A1 (en) * 2020-10-23 2023-12-07 Hq Han Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
IL303198A (en) 2020-11-30 2023-07-01 Mindera Corp Microneedle devices, methods and skin condition tests
US20220373539A1 (en) * 2021-05-24 2022-11-24 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318754D0 (en) 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
US5455160A (en) 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
ES2225956T3 (es) 1996-11-01 2005-03-16 Magne K. Fagerhol Procedimiento para la extraccion de proteinas.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
US7226591B2 (en) 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
ES2316454T3 (es) 2000-08-24 2009-04-16 Genentech, Inc. Metodo de inhibicion de pap1 inducido por il-22.
AU2005220910A1 (en) 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
CA2565701A1 (en) 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
EP3190125A1 (en) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
PL1933869T3 (pl) * 2005-09-01 2010-06-30 Merck Sharp & Dohme Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
US20070203216A1 (en) 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
WO2007098065A2 (en) 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
CA2652924A1 (en) 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17
GB0613470D0 (en) 2006-07-06 2006-08-16 Ares Trading Sa Protein
WO2008028044A2 (en) 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel
EP2426145B1 (en) 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US20090123946A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
CA2702611A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090269777A1 (en) 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
CN101910845A (zh) 2007-11-15 2010-12-08 比奥波托诊断股份公司 个体分子形式的生物标志的诊断用途
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US7879553B2 (en) 2008-03-14 2011-02-01 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome
US20100227775A1 (en) 2008-04-16 2010-09-09 Abbott Laboratories Immunoassays and kits for the detection of ngal
CA2734919C (en) 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
GB2464183A (en) 2008-09-19 2010-04-14 Singulex Inc Sandwich assay
WO2010042903A1 (en) 2008-10-09 2010-04-15 Alfagene Bioscience, Inc Use and identification of biomarkers for gastrointestinal diseases
US20100105150A1 (en) 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
WO2010129964A1 (en) 2009-05-08 2010-11-11 The Board Of Trustees Of The University Of Illinois Drug targets for prevention of arrhythmia in heart disease
EP2435480A1 (en) 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
WO2010151699A1 (en) 2009-06-25 2010-12-29 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP2451969A2 (en) 2009-07-07 2012-05-16 University Of Southern California Biomarkers for the early detection of autoimmune diseases
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
BR112012012513A2 (pt) 2009-11-25 2017-01-10 Prometheus Lab Inc método para diagnosticar síndrome do intestino irritável em um paciente, método para monitorar a progressão ou regressão da síndrome do intestino irritável em um paciente, e para designar uma terapia contra síndrome do intestino irritável a um paciente em necessidade do mesmo
HRP20171939T1 (hr) 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
EP2596022A4 (en) 2010-07-20 2014-11-05 Cephalon Australia Pty Ltd SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23
US8541180B1 (en) 2010-10-11 2013-09-24 Genova Diagnostics, Inc. Compositions and methods for assessing gastrointestinal health
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
JP6116485B2 (ja) 2011-01-06 2017-04-19 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 心臓性突然死に関連する方法において使用するためのｓｃｎ５ａスプライスバリアント
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
WO2012115885A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
EP3825693A1 (en) 2011-04-29 2021-05-26 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
EP2710383B1 (en) 2011-05-16 2017-01-11 The University of Newcastle Performance of a biomarker panel for irritable bowel syndrome
NO20110895A1 (no) 2011-06-21 2012-12-24 Magne Fagerhol Kompetitive S100A9 immunoanalyser
NO336551B1 (no) 2011-06-21 2015-09-28 Magne Fagerhol Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve
CN103874770A (zh) 2011-08-08 2014-06-18 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
CN106063787A (zh) * 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
WO2013132338A2 (en) 2012-03-06 2013-09-12 Calpro As Competitive immunoassay for calprotectin
WO2013132347A2 (en) 2012-03-06 2013-09-12 Calpro As Improved elisa immunoassay for calprotectin
ES2716995T3 (es) 2012-04-03 2019-06-18 Univ Michigan Regents Biomarcadores asociados con el síndrome del intestino irritable y la enfermedad de Crohn
EP2903691B1 (en) * 2012-10-05 2019-05-22 F.Hoffmann-La Roche Ag Methods for diagnosing and treating inflammatory bowel disease
WO2015175856A1 (en) 2014-05-15 2015-11-19 Meso Scale Technologies, Llc. Improved assay methods
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
GB201521357D0 (en) 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
US20200064357A1 (en) 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
WO2018119626A1 (zh) 2016-12-27 2018-07-05 菲鹏生物股份有限公司 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒

Similar Documents

Publication Publication Date Title
JP2018535394A5 (https=)
JP7153775B2 (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP2019508370A5 (https=)
JP6849751B2 (ja) 可溶性ヒトｓｔ−２抗体およびアッセイ法
US20110243893A1 (en) Markers for determination of patient responsiveness
RU2018124603A (ru) Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23
RU2016134838A (ru) Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком
RU2016135417A (ru) Новый анализ для детектирования периостина человека
TWI655433B (zh) 川崎氏症之診斷與治療
JP2014513284A (ja) アルツハイマー病の静注用免疫グロブリン治療におけるサイトカイン濃度の使用
US9835632B2 (en) Biomarker panel for assessment of mucosal healing
Eder et al. Association of serum VEGF with clinical response to anti-TNFα therapy for Crohn’s disease
Fouladseresht et al. Anti-varicella zoster virus IgG and hsCRP levels correlate with progression of coronary artery atherosclerosis
JP2025533470A (ja) Ｈｂｖの診断、予後判定及び治療の方法並びに製品
Codullo et al. Validation of a new immunoenzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis
Mukherjee et al. IL-13 signature in severe adult asthmatics with airway neutrophilia: A new endotype to treat!
CN116323654A (zh) 涉及il-18的抗体的方法及疗法
Guerra et al. Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease
JPWO2020097566A5 (https=)
Tanapon Ussanawarong et al. The Immunogenicity of SARS-CoV-2 Vaccines in Thai Patients with Rheumatoid Arthritis: A Cross-Sectional Study from the National Health Thailand Program
WO2026058045A1 (en) Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
Nerella et al. Demystifying the three different types of COVID-19 associated multisystem inflammatory syndrome in children: Experience from a tertiary care hospital
WO2015166461A1 (en) Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels